{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:16:02Z","timestamp":1779228962940,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570528"],"award-info":[{"award-number":["81570528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8177031729"],"award-info":[{"award-number":["8177031729"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection in patients undergoing haemodialysis is prevalent and aggressive. The treatment of chronic hepatitis C has been revolutionised by the advent of direct\u2010acting antivirals (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s). However, the safety, efficacy, and tolerance of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s in the treatment of acute <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection in patients with end\u2010stage renal disease who are on haemodialysis are unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the safety and efficacy of sofosbuvir plus daclatasvir in this specific, difficult\u2010to\u2010treat population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective and observational study of end\u2010stage renal disease patients who were undergoing haemodialysis and were acutely infected with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>. Patients received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (60 mg) daily. The primary endpoint was the proportion of patients with sustained virological responses (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>s); the other primary outcomes were safety and tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010three patients were enrolled in the study. The median <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> viral load at baseline was 6.8 log<jats:sub>10<\/jats:sub><jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>. Twenty\u2010four patients were infected with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 2a, seven patients with 1b, and two patients with 2a+1b. All patients achieved a <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> at 12 weeks after the end of treatment. The treatment was well tolerated, and there were no drug\u2010related serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (60 mg once daily) were suitable for the treatment of acute <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010infected patients who were undergoing end\u2010stage renal disease and were on haemodialysis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14429","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T09:22:52Z","timestamp":1513588972000},"page":"526-532","source":"Crossref","is-referenced-by-count":18,"title":["Safety and efficacy of sofosbuvir\u2010based treatment of acute hepatitis C in end\u2010stage renal disease patients undergoing haemodialysis"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-3678","authenticated-orcid":false,"given":"Y. L.","family":"He","sequence":"first","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases The Eight Hospital of Xi'an Xi'an China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-6222","authenticated-orcid":false,"given":"C. H.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Haemodialysis Zhen'An County Hospital Zhen'An China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gao","sequence":"additional","affiliation":[{"name":"Xi'an Health School Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. T.","family":"Yan","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-1303","authenticated-orcid":false,"given":"J. F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-6330","authenticated-orcid":false,"given":"Y.","family":"Yang","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. F.","family":"Ren","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. R.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Institution of Hepatology First Affiliated Teaching Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"},{"name":"Department of Infectious Diseases First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'an City China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"S1","article-title":"Kidney disease: improving global outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"81","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv183.40"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22545"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61116-2"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/655682"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4453"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.03.037"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14271"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005555"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001157"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30408-X"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000785"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.391"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14117"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_7_18_1","first-page":"32","article-title":"An update on the management of hepatitis C virus\u2010infected patients with stage 4\u20105 chronic kidney disease while awaiting the revised KDIGO Guidelines","volume":"32","author":"Pol S","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13790"},{"key":"e_1_2_7_20_1","first-page":"736","article-title":"Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data.","volume":"62","author":"Basu P","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_21_1","first-page":"1103","article-title":"Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C. Reply to: \u201cContradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C\u201d","volume":"66","author":"Pawlotsky JM","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_7_22_1","first-page":"667","article-title":"Safety, anti\u2010viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment","volume":"60","author":"Gane EJ","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.044"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24399"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00950208"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T12:13:22Z","timestamp":1695039202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/apt.14429"],"URL":"https:\/\/doi.org\/10.1111\/apt.14429","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,18]]}}}